Author

G. C. M. Smith

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

A. Cerutti· 1 shared A. Cicconi· 1 shared A. Galbiati· 1 shared A. R. Chaudhuri· 1 shared C. Lieftink· 1 shared D. Ebner· 1 shared D. Grande· 1 shared D. Piscitello· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cerutti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models

G. Rodriguez-Berriguete, M. Ranzani, R. Prevo, R. Puliyadi, N. Machado, H. R. Bolland, V. Millar, D. Ebner, M. Boursier, A. Cerutti, A. Cicconi, A. Galbiati, D. Grande, V. Grinkevich, J. Majithiya, , G. S. Higgins

This study shows that Polθ inhibitors ART558 and ART899 radiosensitize tumor cells without affecting normal fibroblasts, suggesting potential for safe cancer radiotherapy.

bioRxiv · Sep 27, 2022Cancer Biology

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps

M. Paes Dias, V. Tripathi, I. v. d. Heijden, K. Cong, E.-M. Manolika, J. Bhin, E. Gogola, P. Galanos, S. Annunziato, C. Lieftink, M. Andujar-Sanchez, S. Chakrabarty, G. C. M. Smith, M. v. d. Ven, R. L. Beijersbergen, , J. Jonkers

This study identifies loss of LIG3 as a factor that reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by increasing ssDNA gaps.

bioRxiv · Mar 24, 2021 · PreprintCancer Biology